Showing results (11-20 of 205) with videos related to

Sort By:
Pageof 21
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 20, 2011
Organized colorectal cancer screening programmes: how to optimize efficiency among general practitionersJérôme Viguier, Anne Calazel-Benque, François Eisinger, et al.
Breast Cancer (Tokyo, Japan)|January 6, 2018
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabineXavier Pivot, Seock Ah Im, Matthew Guo, et al.
Breast (Edinburgh, Scotland)|June 23, 2018
Transmission of breast cancer polygenic risk based on single nucleotide polymorphismsDavid G Cox, Pierre-Etienne Heudel, Julie Henry, et al.
Bulletin Du Cancer|March 1, 2003
[Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck]Armelle Dufresne, Marie Gainet, Ulrich Stein, et al.
Breast (Edinburgh, Scotland)|May 16, 2017
Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective studyJulien Viot, Martin Bachour, Aurélia Meurisse, et al.
Anti-Cancer Drugs|April 7, 2011
Combining molecular targeted therapies: clinical experienceXavier Pivot, Nadia Bedairia, Antoine Thiery-Vuillemin, et al.
Targeted Oncology|August 5, 2020
Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3Diana Lüftner, Gary H Lyman, João Gonçalves, et al.
American Journal of Surgery|April 9, 2008
Predictors of re-excision for positive or close margins in breast-conservation therapy for pT1 tumorsRajeev Ramanah, Xavier Pivot, Jean-Loup Sautiere, et al.
Targeted Oncology|October 20, 2020
Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3Diana Lüftner, Gary H Lyman, João Gonçalves, et al.
Breast Cancer Research and Treatment|February 27, 2020
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysisNoman Paracha, Adriana Reyes, Véronique Diéras, et al.
Pageof 21